Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
The Ministry of Health, Labor and Welfare (MHLW) plans to set up in FY2020 a new study group on the reporting system of inappropriate detailing activities by sales reps from all medical institutions and pharmacies, which started in October. The…
To read the full story
Related Article
- Over 30% of Drug Makers Spot Inappropriate Promotions after Guidelines Enforcement
June 16, 2021
- MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
- MHLW Planning to Launch Report System on Inappropriate Detailing Activity as Early as Summer
May 21, 2019
REGULATORY
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
- MHLW Insurance Chief Vows Thorough Outreach on OTC-Like Drug Charges
September 3, 2026
- MHLW Scraps Routine Reporting for Type 1 Use under Cartagena Act
September 3, 2026
- Japan to Ease Lifetime Blood Donation Ban for Transfusion Recipients
September 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…